Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Applied BioCode Corporation (6598.TW)
Santa Fe Springs, CA, US
Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.07% | +9.21% | +7.52% | -0.82% | +14.35% | +10.45% | +20.90% | -2.80% | -50.46% | -64.20% | -64.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+38.5% ★ Q1'26: +80.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+31.9% ★ Q1'26: +157.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-55.2% Q1'26: -32.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-47.0% Q1'26: +8.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-167.7% Q1'26: +54.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+13.4% Q1'26: +2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.36× Q1'26: 0.83× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
299.02M
est: 300.00M (-0.3%)
|
319.96M
est: 291.00M (+10.0%)
|
390.30M
est: 392.00M (-0.4%)
|
395.17M
est: 467.00M (-15.4%)
|
343.07M
est: 430.00M (-20.2%)
|
475.20M
est: 500.00M (-5.0%)
|
| EBITDA |
-55.56M
est: -100.90M (+44.9%)
|
-111.35M
est: -97.87M (-13.8%)
|
-125.41M
est: -131.84M (+4.9%)
|
-98.59M
est: -157.07M (+37.2%)
|
-197.95M
est: -158.86M (-24.6%)
|
-166.96M
est: -184.72M (+9.6%)
|
| EBIT |
-99.16M
est: -148.15M (+33.1%)
|
-162.31M
est: -143.70M (-12.9%)
|
-181.93M
est: -193.58M (+6.0%)
|
-161.28M
est: -230.61M (+30.1%)
|
-259.35M
est: -224.24M (-15.7%)
|
-223.33M
est: -260.75M (+14.3%)
|
| Net Income |
-103.50M
est: -114.68M (+9.7%)
|
-165.20M
est: -204.54M (+19.2%)
|
-184.73M
est: -195.12M (+5.3%)
|
-164.20M
est: -136.93M (-19.9%)
|
-260.81M
est: -172.68M (-51.0%)
|
-201.20M
est: -172.46M (-16.7%)
|
| SGA |
130.03M
est: 151.21M (-14.0%)
|
148.46M
est: 146.67M (+1.2%)
|
188.40M
est: 197.58M (-4.6%)
|
209.15M
est: 235.39M (-11.1%)
|
209.05M
est: 212.84M (-1.8%)
|
185.13M
est: 247.49M (-25.2%)
|
| EPS |
-1.33
est: -1.27 (-5.0%)
|
-2.02
est: -2.26 (+10.6%)
|
-2.26
est: -2.15 (-4.9%)
|
-2.01
est: -1.51 (-32.9%)
|
-2.88
est: -1.68 (-71.2%)
|
-1.96
est: -1.68 (-16.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jaca Liang-Kai Huang | Chief Financial Officer & Corporate Governance Officer | 6M | male |
| Winston Z. | Founder, Chief Executive Officer, President & Director | 42.0K | — |
| Jim Leigh | Vice President of Sales | — | male |
| Parisa Hanachi | Vice President of Marketing | — | female |
| Ruei-E Tang | Administration Division Director | — | female |
| Yu-Tsung Chou | Chief Information Officer | — | — |
| Beth Laderman | Chief Scientific Officer | — | — |
| Zhao Gu Chen | Accounting Director | — | — |
| Ingrid Joseph | Administration Division Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6598.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
